Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort.

MLA

Ri, Masaki, et al. “Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma: CARTITUDE‐1 (Phase 2) Japanese Cohort.” Cancer Science, vol. 113, no. 12, Dec. 2022, pp. 4267–76. EBSCOhost, https://doi.org/10.1111/cas.15556.

APA

Ri, M., Suzuki, K., Ishida, T., Kuroda, J., Tsukamoto, T., Teshima, T., Goto, H., Jackson, C. C., Sun, H., Pacaud, L., Fujikawa, E., Yeh, T., Hatayama, T., Aida, K., Sunagawa, Y., & Iida, S. (2022). Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort. Cancer Science, 113(12), 4267–4276. https://doi.org/10.1111/cas.15556

Chicago

Ri, Masaki, Kenshi Suzuki, Tadao Ishida, Junya Kuroda, Taku Tsukamoto, Takanori Teshima, Hideki Goto, et al. 2022. “Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma: CARTITUDE‐1 (Phase 2) Japanese Cohort.” Cancer Science 113 (12): 4267–76. doi:10.1111/cas.15556.